# Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency - FDA Guidance Document

Source: https://www.globalkeysolutions.net/guidances/guidance-document/antiviral-product-development-conducting-and-submitting-virology-studies-to-the-agency/81122360-623f-492b-84a2-d1ef7e31728f

> FDA guidance document: Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency. Issue date: June 05, 2006. Get complete insights and analysis.

---

## Details

- Title: Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency
- Communication Type: Guidance Document
- Product Type: drugs
- Office Name: Center for Drug Evaluation and Research
- Office URL: /offices/center-for-drug-evaluation-and-research/cd980d74-1cbf-4226-ba9a-9045324c236c
- Issue Date: 2006-06-05
- Last Changed: 2020-04-24
- Docket Number: <a href="https://www.regulations.gov/docket/FDA-2005-D-0282">FDA-2005-D-0282</a>

## Related Documents

- [Role of HIV Drug Resistance Testing in Antiretroviral Drug Development](https://www.globalkeysolutions.net/guidances/guidance-document/role-of-hiv-drug-resistance-testing-in-antiretroviral-drug-development/b63afac3-86d1-45b1-bee0-b25944c92926)
- [Nonclinical Safety Evaluation of Pediatric Drug Products](https://www.globalkeysolutions.net/guidances/guidance-document/nonclinical-safety-evaluation-of-pediatric-drug-products/a5729b5c-7a6e-40c1-861d-e8acf3cd178a)
- [Internal Radioactive Contamination —Development of Decorporation Agents](https://www.globalkeysolutions.net/guidances/guidance-document/internal-radioactive-contamination-development-of-decorporation-agents/2c9ecc52-8f94-400c-a1be-8bf28a25e1a8)